ICU MEDICAL INC/DE
ICUINasdaq
$157.51
↓ -2.9%Jul 17 close · end-of-day
Price
1Y↑ +26.2%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$4.0B
Enterprise Value
$5.2B
P/E
84.7
P/S
1.8
P/B
1.9
EV/EBITDA
21.4
PEG
—
FCF Yield
2.1%
Dividend Yield
—
Revenue (TTM)
$2.2B
Net Income (TTM)
$46.3M
Free Cash Flow (TTM)
$82.7M
Gross Margin
37.9%
Operating Margin
2.0%
Net Margin
2.1%
ROE
2.2%
ROIC
1.3%
Debt / Equity
0.6
Net Cash
-$1.3B
Return 1Y
+26.3%
Company profile
ICU Medical, Inc. develops, manufactures, and sells medical devices used in infusion therapy and critical care applications. The company's infusion therapy products include needlefree products; Neutron catheter patency devices; SwabCap and SwabTip disinfecting caps. It also provides critical care products, such as Cogent 2-in-1 and CardioFlo hemodynamic monitoring systems.
- CEO
- Vivek Jain
- Sector
- Manufacturing
- Industry
- Medical Equipment
- Employees
- 14,500
- Headquarters
- California
- Website
- icumed.com
Management & directors
- Woolson DanielVP, GM-Infusion Capital
- Sanzone Virginia RuthVP, General Counsel
- Bonnell Brian MichaelChief Financial Officer
- Jain VivekChairman and CEO
- Sousa BenChief Information Officer
- Voigtlander Christian B.Chief Operating Officer
Roles derived from SEC Form 4 filings.
Earnings
ICUI Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$530.2M↓ -12.3%
Diluted EPS$1.20↓ -290.5%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $1.3B | $1.3B | $2.3B | $2.3B | $2.4B | $2.2B |
| Gross profit | $461.5M | $491.5M | $697.8M | $739.9M | $824.8M | $822.0M |
| Operating income | $98.2M | $123.2M | -$42.9M | $22.8M | $43.0M | $42.8M |
| Net income | $86.9M | $103.1M | -$74.3M | -$29.7M | -$117.7M | $732,000.00 |
| Diluted EPS | $4.02 | $4.74 | -$3.11 | -$1.23 | -$4.83 | $0.03 |
| Operating cash flow | $222.8M | $267.5M | -$62.1M | $166.2M | $204.0M | $179.8M |
| Free cash flow | $130.7M | $199.0M | -$152.4M | $82.3M | $124.7M | $91.8M |
| Gross margin | 36.3% | 37.3% | 30.6% | 32.8% | 34.6% | 36.8% |
| Operating margin | 7.7% | 9.4% | -1.9% | 1.0% | 1.8% | 1.9% |
| Net margin | 6.8% | 7.8% | -3.3% | -1.3% | -4.9% | 0.0% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $596.5M | $589.1M | $629.8M | $604.7M | $548.9M | $537.0M | $540.7M | $530.2M |
| Gross profit | $207.4M | $204.9M | $227.3M | $210.1M | $208.1M | $200.9M | $203.0M | $206.2M |
| Operating income | $7.7M | $8.2M | $37.7M | $12.9M | $10.6M | $13.7M | $5.6M | $13.6M |
| Net income | -$21.4M | -$33.0M | -$23.8M | -$15.5M | $35.3M | -$3.4M | -$15.7M | $30.1M |
| Diluted EPS | -$0.88 | -$1.35 | -$0.97 | -$0.63 | $1.43 | -$0.14 | -$0.63 | $1.20 |
| Operating cash flow | $82.0M | $36.1M | $40.2M | $51.3M | $11.2M | $56.7M | $60.6M | $38.9M |
| Free cash flow | $62.5M | $16.2M | $16.1M | $36.7M | -$8.5M | $27.6M | $36.0M | $27.6M |
| Gross margin | 34.8% | 34.8% | 36.1% | 34.7% | 37.9% | 37.4% | 37.5% | 38.9% |
| Operating margin | 1.3% | 1.4% | 6.0% | 2.1% | 1.9% | 2.6% | 1.0% | 2.6% |
| Net margin | -3.6% | -5.6% | -3.8% | -2.6% | 6.4% | -0.6% | -2.9% | 5.7% |
Company news
Jul 10, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-05-22 | Woolson Daniel· President | Sale | 2,123 | $132.21 | $280,684.80 | filing |
| 2026-05-14 | Sanzone Virginia Ruth· VP, General Counsel | Sale | 2,447 | $124.08 | $303,623.76 | filing |
| 2026-05-13 | Hernandez Laurie | Option exercise | 1,254 | $0.00 | $0.00 | filing |
| 2026-05-13 | FINNEY ELISHA W | Option exercise | 1,254 | $0.00 | $0.00 | filing |
| 2026-05-13 | Hoffmeister David F | Option exercise | 1,254 | $0.00 | $0.00 | filing |
| 2026-05-13 | Greenberg David C. | Option exercise | 1,254 | $0.00 | $0.00 | filing |
| 2026-05-13 | Abbey Donald | Option exercise | 1,254 | $0.00 | $0.00 | filing |
| 2026-05-13 | KENNEDY KOLLEEN T | Option exercise | 1,254 | $0.00 | $0.00 | filing |
| 2026-05-12 | Greenberg David C. | Sale | 2,424 | $122.91 | $297,933.84 | filing |
| 2026-05-12 | Greenberg David C. | Option exercise | 2,424 | $101.06 | $244,969.44 | filing |
| 2026-03-25 | Abbey Donald | J | 704 | $0.00 | $0.00 | filing |
| 2026-03-15 | Jain Vivek· Chairman and CEO | Tax withholding | 9,452 | $125.85 | $1.2M | filing |
| 2026-03-15 | Voigtlander Christian B.· Chief Operating Officer | Tax withholding | 6,301 | $125.85 | $792,980.85 | filing |
| 2026-03-15 | Bonnell Brian Michael· Chief Financial Officer | Tax withholding | 5,800 | $125.85 | $729,930.00 | filing |
| 2026-03-15 | Sanzone Virginia Ruth· VP, General Counsel | Tax withholding | 3,150 | $125.85 | $396,427.50 | filing |
| 2026-03-15 | Jain Vivek· Chairman and CEO | Tax withholding | 2,693 | $125.85 | $338,914.05 | filing |
| 2026-03-15 | Bonnell Brian Michael· Chief Financial Officer | Tax withholding | 1,795 | $125.85 | $225,900.75 | filing |
| 2026-03-15 | Voigtlander Christian B.· Chief Operating Officer | Tax withholding | 1,795 | $125.85 | $225,900.75 | filing |
| 2026-03-15 | Woolson Daniel· VP, GM-Infusion Capital | Tax withholding | 1,295 | $125.85 | $162,975.75 | filing |
| 2026-03-15 | Sanzone Virginia Ruth· VP, General Counsel | Tax withholding | 897 | $125.85 | $112,887.45 | filing |
| 2026-03-15 | Sousa Ben· Chief Information Officer | Tax withholding | 718 | $125.85 | $90,360.30 | filing |
| 2026-03-15 | Sanzone Virginia Ruth· VP, General Counsel | Option exercise | 1,624 | $0.00 | $0.00 | filing |
| 2026-03-15 | Sousa Ben· Chief Information Officer | Option exercise | 1,300 | $0.00 | $0.00 | filing |
| 2026-03-15 | Jain Vivek· Chairman and CEO | Option exercise | 17,100 | $0.00 | $0.00 | filing |
| 2026-03-15 | Sanzone Virginia Ruth· VP, General Counsel | Option exercise | 5,700 | $0.00 | $0.00 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.